biote Corp.
NASDAQ:BTMD · NASDAQ Global Market
+$0.03 today
Vol 0.20M · Avg 0.27M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-46.2%
avg 71.0%
ROIC
47.3%
avg 53.5%
ROA
25.1%
avg 38.2%
Analysis
ROIC is currently the strongest return metric at 47.3% versus its period average of 53.5%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Mary Elizabeth Conlon | Vice President of Business Development, General Counsel & Corporate Secretary | $1.27M | — | 45 | $178,000.00 | 0.40% |
Bret Christensen | Chief Executive Officer & Director | $1.13M | — | 55 | $130,000.00 | 0.29% |
Robert Peterson | Chief Financial Officer and Chief Business Officer | $675,613.00 | — | 49 | $107,169.00 | 0.24% |
Komal Bajaj | Chief Medical Officer | — | — | — | — | — |
Dan Monico | General Counsel | — | — | — | $88,800.00 | 0.20% |
Joey Lopes | SVP of Strategy & Commercial Operations | — | — | — | — | — |
John J. Olsen | Chief Information Officer | — | — | 69 | — | — |
Richard Kevin Key | Chief Digital Officer | — | — | 55 | $121,452.00 | 0.28% |
Joel Pickering | Chief Marketing Officer | — | — | — | — | — |
Cory Rice | Chief Clinical Advisor & Member of Medical Advisory Board | — | — | — | — | — |
Jade Beutler | Head of Nutraceuticals | — | — | 62 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -67.7% | +26.9% (7yr)1 analysts |
| Revenue | N/A | N/A | +16.7% | +3.9% (7yr)1 analysts |
| Net Income | N/A | N/A | -51.6% | +33.7% (7yr)1 analysts |
| EBIT | N/A | N/A | -3.4% | +12.9% (7yr)1 analysts |
Analysis
Recent growth has been strongest in Revenue at +16.7% over three years. Forward estimates point to Net Income at +33.7% (7yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Anika Therapeutics, Inc.
NASDAQ:ANIK
$195.86M
Spero Therapeutics, Inc.
NASDAQ:SPRO
$165.02M
Acumen Pharmaceuticals, Inc.
NASDAQ:ABOS
$143.56M
The Joint Corp.
NASDAQ:JYNT
$136.57M
Vor Biopharma Inc.
NASDAQ:VOR
$98.42M
Lucid Diagnostics Inc.
NASDAQ:LUCD
$98.28M
Scilex Holding Company
NASDAQ:SCLX
$72.18M
Inovio Pharmaceuticals, Inc.
NASDAQ:INO
$58.95M
Seres Therapeutics, Inc.
NASDAQ:MCRB
$55.20M
Actuate Therapeutics Inc
ACTU
$48.33M
Who manages BTMD?
biote Corp. (BTMD) lists 11 active executives. The top listed executive is Komal Bajaj, Chief Medical Officer.
Are BTMD insiders buying or selling?
Recent insider activity shows net buying of $30.12M.
Explore More
Continue the stock analysis
Jump to another research area for this company.